A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

August 26, 2026 updated by: Verastem, Inc.

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

180

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Australia
      • South Brisbane, Australia, QLD 4101
        • Recruiting
        • ICON Cancer Centre
        • Principal Investigator:
          • Jermaine Coward, MD
        • Contact:
    • New South Wales
      • Sydney, New South Wales, Australia, 2019
        • Recruiting
        • Macquarie University Hospital
        • Contact:
        • Principal Investigator:
          • Wei Yen Chan, MD
    • South Australia
      • Kurralta Park, South Australia, Australia, 5037
        • Recruiting
        • ICON Kurralta Park
        • Contact:
        • Principal Investigator:
          • Carolyn Bampton, MD
  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
      • Toronto, Ontario, Canada, M5G 2M9
        • Recruiting
        • Princess Margaret Cancer Center
        • Principal Investigator:
          • Jennifer Knox, MD
        • Contact:
  • United States
    • California
      • Los Angeles, California, United States, 90048
        • Recruiting
        • Cedars-Sinai Medical Center
        • Principal Investigator:
          • Arsen Osipov, MD
        • Contact:
      • Los Angeles, California, United States, 90067
        • Recruiting
        • Valkyrie Clinical Trials
        • Principal Investigator:
          • David Berz, MD
        • Contact:
      • Los Angeles, California, United States, 90025
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Recruiting
        • Mayo Clinical Florida
        • Contact:
          • Clinical Trials Referral Office
          • Phone Number: 855-776-0015
        • Principal Investigator:
          • Umair Majeed, MD
      • Tampa, Florida, United States, 33612
        • Recruiting
        • Moffitt Cancer Center
        • Contact:
        • Principal Investigator:
          • Dae-Won Kim, MD
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Recruiting
        • Johns Hopkins University
        • Contact:
        • Principal Investigator:
          • Mari Nakazawa, MD
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Recruiting
        • Massachusetts General Hospital
        • Principal Investigator:
          • Harshabad Singh, MD
        • Contact:
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Dana-Farber Cancer Institute
        • Principal Investigator:
          • Kimberly Perez, MD
        • Contact:
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Recruiting
        • University of Michigan
        • Principal Investigator:
          • Vaibhav Sahai, MD
        • Contact:
      • Grand Rapids, Michigan, United States, 49546
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinical Rochester
        • Contact:
          • Clinical Trial Referral Office
          • Phone Number: 855-776-0015
        • Principal Investigator:
          • Ryan Carr, MD
    • Missouri
      • St Louis, Missouri, United States, 63110
        • Recruiting
        • Washington University
        • Principal Investigator:
          • Kian-Huat Lim, MD
        • Contact:
    • New Jersey
      • East Brunswick, New Jersey, United States, 08816
    • New York
      • New York, New York, United States, 10016
        • Recruiting
        • NYU-Manhattan
        • Principal Investigator:
          • Kristen Spencer, MD
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • Recruiting
        • University of North Carolina
        • Principal Investigator:
          • Ashwin Somasundaram, MD
        • Contact:
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Sarah Cannon Research Institute
        • Principal Investigator:
          • Meredith Pelster, MD
        • Contact:
    • Texas
      • Fort Worth, Texas, United States, 76104
      • Houston, Texas, United States, 77054
        • Recruiting
        • MD Anderson Cancer Center
        • Principal Investigator:
          • Shubham Pant, MD
        • Contact:
      • San Antonio, Texas, United States, 78229
    • Utah
      • West Valley City, Utah, United States, 84119
    • Virginia
      • Charlottesville, Virginia, United States, 22903
        • Recruiting
        • UVA Health
        • Principal Investigator:
          • Matthew Reilley, MD
        • Contact:
      • Fairfax, Virginia, United States, 22031
    • Washington
      • Seattle, Washington, United States, 98101
        • Recruiting
        • Virginia Mason
        • Principal Investigator:
          • Vincent Picozzi, MD
        • Contact:
    • Wisconsin
      • Madison, Wisconsin, United States, 53792
        • Recruiting
        • UW Health
        • Principal Investigator:
          • Noelle LoConte, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Histopathology confirmed PDAC
  • Measurable disease per RECIST 1.1
  • Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • ECOG PS=0 or 1

Adequate organ function

VS-7375 + cetuximab (2L PDAC) :

-Received only 1 prior Tx in the metastatic setting; prior adjuvant counts as a line if progressed within 6 months

VS-7375 + cetuximab (1L PDAC) :

-Treatment-naïve or received ≤ 1 cycle of SoC for metastatic disease

Exclusion criteria:

  • Have any other documented co-existing common RAS mutation(s)
  • Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
  • Major surgery within 4 weeks of first treatment dose
  • Radiation therapy (RT) within 1 week of first treatment dose; RT to brain or lung within 2 weeks of first treatment dose
  • History of drug-induced Interstitial Lung Disease
  • Receipt of prior direct RAS inhibitor
  • Untreated or symptomatic CNS metastasis
  • Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
  • Receipt of PPI or H2 blocker within 5 days
  • Inability to swallow oral medication
  • Other protocol-defined inclusion/exclusion criteria may apply

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: VS-7375 Monotherapy
Drug: VS-7375
Taken by mouth
Experimental: VS-7375 + cetuximab 2L PDAC
Drug: VS-7375
Taken by mouth
Drug: cetuximab
Subcutaneous infusion
Experimental: VS-7375 + cetuximab 1L PDAC
Drug: VS-7375
Taken by mouth
Drug: cetuximab
Subcutaneous infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1
Time Frame: 6 months
Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)
6 months
To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.
Time Frame: 6 months
Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments.
Time Frame: 24 months
To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab, administered on a daily oral schedule in participants with KRAS G12D-mutated PDAC.
24 months
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax
Time Frame: 20 weeks
Maximum concentration (Cmax)
20 weeks
Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC
Time Frame: 20 weeks
Area under plasma Concentration (AUC) 0 to t
20 weeks
To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type
Time Frame: Up to 2.5 years
CA19-9, CEA, CA-125
Up to 2.5 years
To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)
Time Frame: 24 months
The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of pancreatic ductal adenocarcinoma patients
24 months
Time to next therapy.
Time Frame: 24 months
To assess the interval between initiation of study treatment and initiation of subsequent
24 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Imaging of tumor metabolism changes
Time Frame: 24 months
To assess tumor metabolism dynamics on FDG-PET/CT
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Verastem, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 16, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

May 26, 2026

First Submitted That Met QC Criteria

June 8, 2026

First Posted (Actual)

June 12, 2026

Study Record Updates

Last Update Posted (Actual)

August 31, 2026

Last Update Submitted That Met QC Criteria

August 26, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • VS-7375-201

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe